Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 2
2008 3
2009 3
2010 4
2011 4
2012 3
2013 9
2014 11
2015 8
2016 10
2017 17
2018 21
2019 18
2020 29
2021 33
2022 20
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
Takahashi A, Nomoto H, Onishi K, Manda S, Miya A, Kameda H, Nakamura A, Atsumi T. Takahashi A, et al. Among authors: nakamura a. Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15639. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38699794 No abstract available.
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
Nomoto H, Furusawa S, Yokoyama H, Suzuki Y, Izumihara R, Oe Y, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Kurihara Y, Nakamura A, Atsumi T. Nomoto H, et al. Among authors: nakamura a. J Clin Endocrinol Metab. 2024 May 2:dgae213. doi: 10.1210/clinem/dgae213. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38695547
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
Furusawa S, Nomoto H, Oba-Yamamoto C, Takeuchi J, Ito M, Kurihara H, Aoki S, Miya A, Kameda H, Nakamura A, Atsumi T. Furusawa S, et al. Among authors: nakamura a. Endocr J. 2024 Apr 25. doi: 10.1507/endocrj.EJ23-0648. Online ahead of print. Endocr J. 2024. PMID: 38658349 Free article.
Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
Izumihara R, Nomoto H, Kito K, Yamauchi Y, Omori K, Shibayama Y, Yanagiya S, Miya A, Kameda H, Cho KY, Nagai S, Sakuma I, Nakamura A, Atsumi T; PARM-T2D Study Group. Izumihara R, et al. Among authors: nakamura a. Diabetes Metab J. 2024 Feb 29. doi: 10.4093/dmj.2023.0370. Online ahead of print. Diabetes Metab J. 2024. PMID: 38419467 Free article.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T; SWITCH-SEMA 2 study group. Furusawa S, et al. Among authors: nakamura a. Diabetes Obes Metab. 2024 Mar;26(3):961-970. doi: 10.1111/dom.15393. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073422 Clinical Trial.
166 results